How to buy Guided Therapeutics stock (Guided Therapeutics)

Guided Therapeutics is conducting an offering of units comprised of one share and one warrant exercisable for one share. The deal is contingent upon the approval of its application for listing on the Nasdaq.

The company's stock is currently traded on the Over-the-Counter Markets.

We'll update this page as new information becomes available.

Our top picks for where to buy Guided Therapeutics stock

Buy Guided Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Guided Therapeutics stock price (OTCQB: GTHP)

Use our graph to track the performance of GTHP stocks over time.

Guided Therapeutics shares at a glance

• Key figures

Information last updated 2024-11-21.

Latest market close	$0.13
52-week range	$0.06 - $0.23
50-day moving average more info button	$0.17
200-day moving average more info button	$0.13
Wall St. target price	N/A
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.03

Is it a good time to buy Guided Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Guided Therapeutics price performance over time

Historical closes compared with the close of $0.17 from 2024-12-19

1 week (2024-12-13)	-2.30%
1 month (2024-11-21)	-5.03%
3 months (2024-09-20)	6.25%
6 months (2024-06-21)	68.32%

1 year (2023-12-21)	25.00%
2 years (2022-12-21)	-50.29%
3 years (2021-12-21)	0.61
5 years (2019-12-20)	3.03%

Guided Therapeutics financials

Revenue TTM	$38,000
Gross profit TTM	$-68,000
Return on assets TTM	-73.67%
Return on equity TTM	0%
Profit margin	0%
Book value	$-0.13
Market Capitalization more info button	$11.9 million

TTM: trailing 12 months

Guided Therapeutics share dividends

We're not expecting Guided Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

• Pfizer (PFE.US) (6.64% forward annual dividend yield)

Have Guided Therapeutics's shares ever split?

Guided Therapeutics's shares were split on a 1:800 basis on 28 March 2019 . So if you had owned 800 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Guided Therapeutics shares – just the quantity. However, indirectly, the new 79900% higher share price could have impacted the market appetite for Guided Therapeutics shares which in turn could have impacted Guided Therapeutics's share price.

Guided Therapeutics share price volatility

Over the last 12 months, Guided Therapeutics's shares have ranged in value from as little as $0.064 up to $0.23. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (OTCQB average) beta is 1, while Guided Therapeutics's is 0.502. This would suggest that Guided Therapeutics's shares are less volatile than average (for this exchange).

To put Guided Therapeutics's beta into context you can compare it against those of similar companies.

• BioNTech (BNTX.US): 0.259
• Moderna (MRNA.US): 1.69
• Pfizer (PFE.US): 0.615

Guided Therapeutics overview

Guided Therapeutics, Inc. , a medical technology company, develops medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc.

Frequently asked questions

null
What percentage of Guided Therapeutics is owned by insiders or institutions?
Currently 44.086% of Guided Therapeutics shares are held by insiders and 6.692% by institutions. How many people work for Guided Therapeutics?
Latest data suggests 4 work at Guided Therapeutics. When does the fiscal year end for Guided Therapeutics?
Guided Therapeutics's fiscal year ends in December. Where is Guided Therapeutics based?
Guided Therapeutics's address is: 5835 Peachtree Corners East, Peachtree Corners, GA, United States, 30092